Skip to content

Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement

Multicenter Study to Evaluate the Safety and Performance of the Quantum Surgical Robotic Device for Image-guided Percutaneous Needle Placement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04230642
Enrollment
22
Registered
2020-01-18
Start date
2020-05-25
Completion date
2021-02-02
Last updated
2021-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Tumor

Brief summary

This study evaluates the safety and performance of a new robotic device in the treatment of hepatic thermoablation in adults. The new robotic device will be used in all patients.

Detailed description

The device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of needle, as well as in verification of needle position during CT guided percutaneous ablation procedures. After validation of the correct positioning of the needle, the tumor ablation procedure is conducted with a device routinely used by the investigator. The Acquisition of a post-interventional CT-guided image is realized to evaluate adverse events occurrence.

Interventions

DEVICEThe Quantum Surgical device

Robotic platform for needle placement

Sponsors

Quantum Surgical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient is at least 18 years old, * Patient for whom an ablation procedure under CT guidance in liver organ has been prescribed and consensually agreed by a multidisciplinary team of radiologists, surgeons and clinicians, * Patient not taking platelet antiaggregant or having stopped taking it for 5 days and not taking anticoagulant (thrombocytes ≥ 50 000/mm3, TP \> 50%), * Patient who agrees to participate in the evaluation and who has signed the inform consent, * Patient covered by social security system.

Exclusion criteria

* Patient unable to undergo general anesthesia, * Patient unable to tolerate CT contrast agent * Patient already participating in another clinical study * Pregnant or breast-feeding woman.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the safety related to the procedureDuring the procedureNumber of Adverse Event(s) that are considered to be major and are attributable to the needle insertion phase of the procedure
Evaluation of the feasibility of the Quantum Surgical device: Number of targets reachedDuring the procedureNumber of targets reached; the target is considered to have been reached when the needle is positioned accurately enough to allow the next step of the procedure to be carried out

Secondary

MeasureTime frameDescription
Evaluation of the accuracy of the deviceThrough study completion, an average of 1 monthAssessment of the needle placement accuracy (distance from the needle tip to the target)
Evaluation of the needle readjustments of the deviceDuring the procedureAssessment of the number of needle readjustments to reach the target
Evaluation of the safety not related to the procedureThrough study completion, an average of 1 monthAll Adverse Event(s) except those considered major and are attributable to the needle insertion phase of the procedure

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026